Trimethoprim-sulfamethoxazole Versus Placebo To Reduce The Risk Of Recurrences Of Toxoplasma Gondii Retinochoroiditis: Randomized Controlled Clinical Trial.

dc.creatorFelix, João Paulo Fernandes
dc.creatorLira, Rodrigo Pessoa Cavalcanti
dc.creatorZacchia, Rafael Santos
dc.creatorToribio, Jaqueline Machado
dc.creatorNascimento, Mauricio Abujamra
dc.creatorArieta, Carlos Eduardo Leite
dc.date2014-Apr
dc.date2015-11-27T13:41:43Z
dc.date2015-11-27T13:41:43Z
dc.date.accessioned2018-03-29T01:19:29Z
dc.date.available2018-03-29T01:19:29Z
dc.identifierAmerican Journal Of Ophthalmology. v. 157, n. 4, p. 762-766.e1, 2014-Apr.
dc.identifier1879-1891
dc.identifier10.1016/j.ajo.2013.12.022
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/24388839
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/201071
dc.identifier24388839
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1301304
dc.descriptionTo compare the effects of trimethoprim-sulfamethoxazole vs placebo in reducing the risk of recurrences of Toxoplasma gondii retinochoroiditis. Single-center, prospective randomized double-masked clinical trial. A total of 95 patients from Campinas, Brazil, with active recurrent Toxoplasma gondii retinochoroiditis were included. The initially active toxoplasmosis lesions were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days. Subsequently, 5 patients dropped out of the study. The remaining patients were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Group 2 (identical placebo tablet every 2 days). Randomization was 1:1, was stratified by sex, and used block sizes of 4. The primary outcome was recurrent toxoplasmosis retinochoroiditis within 1 year, and the secondary outcome was a 1-year change in best-corrected visual acuity (BCVA) (ETDRS chart). The incidence of recurrent toxoplasmosis retinochoroiditis within 12 months was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respectively (P = .026). Visual acuity improvements in the 2 groups were similar. No treatment-limiting toxicity was observed. Trimethoprim/sulfamethoxazole therapy resulted in a 100% reduction in the recurrence of Toxoplasma gondii retinochoroiditis over 1 year of treatment.
dc.description157
dc.description762-766.e1
dc.languageeng
dc.relationAmerican Journal Of Ophthalmology
dc.relationAm. J. Ophthalmol.
dc.rightsfechado
dc.rightsCopyright © 2014 Elsevier Inc. All rights reserved.
dc.sourcePubMed
dc.subjectAdult
dc.subjectAnti-infective Agents
dc.subjectChorioretinitis
dc.subjectDouble-blind Method
dc.subjectFemale
dc.subjectFollow-up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectProspective Studies
dc.subjectSecondary Prevention
dc.subjectToxoplasma
dc.subjectToxoplasmosis, Ocular
dc.subjectTrimethoprim-sulfamethoxazole Combination
dc.subjectVisual Acuity
dc.titleTrimethoprim-sulfamethoxazole Versus Placebo To Reduce The Risk Of Recurrences Of Toxoplasma Gondii Retinochoroiditis: Randomized Controlled Clinical Trial.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución